文献速递肝病

氯沙坦治疗儿童非酒精性脂肪性肝病的随机安慰剂对照试验

Randomized placebo-controlled trial of losartan for pediatric NAFLD.
PubMed 文献 · Hepatology · 2022-02-28

多中心双盲随机安慰剂对照试验纳入83例组织学确诊的非酒精性脂肪性肝病(NAFLD)儿童,随机接受氯沙坦100 mg每日一次或安慰剂治疗24周。氯沙坦组与安慰剂组丙氨酸氨基转移酶(ALT)变化无显著差异,但氯沙坦组碱性磷酸酶和收缩压显著降低。

要点

  • 氯沙坦100 mg每日一次治疗24周未显著降低NAFLD儿童ALT水平。
  • 氯沙坦组碱性磷酸酶和收缩压较安慰剂组显著降低。
  • 因无效性提前终止,样本量83例低于预设110例。

核心结论

  • 与安慰剂相比,氯沙坦未显著降低NAFLD儿童的ALT水平。

研究设计与样本

  • 非酒精性脂肪性肝炎临床研究网络在10个中心开展的多中心、双盲、安慰剂对照、随机临床试验(2018年9月至2020年4月)。
  • 纳入8-17岁、组织学NAFLD活动度评分≥3且血清ALT≥50 U/l的儿童,预设样本量110例。
  • 儿童随机接受氯沙坦100 mg或安慰剂口服每日一次,治疗24周;主要结局为基线至24周ALT变化。

主要发现

  • 83例参与者(81%男性,80%西班牙裔)随机分配至氯沙坦组(n=43)或安慰剂组(n=40)。
  • 24周ALT变化在氯沙坦组与安慰剂组间无显著差异(校正均数差:1.1 U/l;95%CI=-30.6,32.7;p=0.95)。
  • 氯沙坦组碱性磷酸酶显著降低(校正均数差:-23.4 U/l;95%CI=-41.5,-5.3;p=0.01)。
  • 收缩压氯沙坦组降低而安慰剂组升高(校正均数差:-7.5 mm Hg;95%CI=-12.2,-2.8;p=0.002)。
  • 片剂计数依从性及不良事件数量和类型组间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因2019冠状病毒疾病大流行导致入组暂停,计划外中期分析显示组间显著差异概率低(7%),数据与安全监察委员会建议提前终止研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: To date, no pharmacotherapy exists for pediatric NAFLD. Losartan, an angiotensin II receptor blocker, has been proposed as a treatment due to its antifibrotic effects. APPROACH AND RESULTS: The Nonalcoholic Steatohepatitis Clinical Research Network conducted a multicenter, double-masked, placebo-controlled, randomized clinical trial in children with histologically confirmed NAFLD at 10 sites (September 2018 to April 2020). Inclusion criteria were age 8-17 years, histologic NAFLD activity score ≥ 3, and serum alanine aminotransferase (ALT) ≥ 50 U/l. Children received 100 mg of losartan or placebo orally once daily for 24 weeks. The primary outcome was change in ALT levels from baseline to 24 weeks, and the preset sample size was n = 110. Treatment effects were assessed using linear regression of change in treatment group adjusted for baseline value. Eighty-three participants (81% male, 80% Hispanic) were randomized to losartan (n = 43) or placebo (n = 40). During an enrollment pause, necessitated by the 2019 coronavirus pandemic, an unplanned interim analysis showed low probability (7%) of significant group difference. The Data and Safety Monitoring Board recommended early study termination. Baseline characteristics were similar between groups. The 24-week change in ALT did not differ significantly between losartan versus placebo groups (adjusted mean difference: 1.1 U/l; 95% CI = -30.6, 32.7; p = 0.95), although alkaline phosphatase decreased significantly in the losartan group (adjusted mean difference: -23.4 U/l; 95% CI = -41.5, -5.3; p = 0.01). Systolic blood pressure decreased in the losartan group but increased in placebo (adjusted mean difference: -7.5 mm Hg; 95% CI = -12.2, -2.8; p = 0.002). Compliance by pill counts and numbers and types of adverse events did not differ by group. CONCLUSIONS: Losartan did not significantly reduce ALT in children with NAFLD when compared with placebo.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vos MB, Van Natta ML, Blondet NM, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022. PMID: 35133671. doi:10.1002/hep.32403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。